FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:844-846 August 30, 2007 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

On July 30, 2007, the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration (FDA) convened to discuss the myocardial ischemic risk associated with rosiglitazone treatment in patients with type 2 diabetes mellitus. The joint committee, which I chaired, consisted of 24 experts in cardiovascular disease, epidemiology, biostatistics, and endocrinology. After lengthy discussions, we concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated with a greater risk of myocardial ischemic events than placebo, metformin, or sulfonylureas.

That conclusion was based primarily on . . . [Full Text of this Article]

Source Information

Dr. Rosen is an endocrinologist and a senior staff scientist at the Maine Center for Osteoporosis, St. Joseph Hospital, Bangor, and the Jackson Laboratory, Bar Harbor — both in Maine.

This article (10.1056/NEJMp078167) was published at www.nejm.org on August 8, 2007.

Related Letters:

Rosiglitazone and the FDA
Joffe H. V., Parks M. H., Meyer R. J., Jenkins J. K., Temple R., Krall R. L., Rosen C. J.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1775-1777, Oct 25, 2007; published at www.nejm.org on Aug 29, 2007 (10.1056/NEJMc076347). Correspondence

Rosiglitazone and the FDA
Joffe H. V., Parks M. H., Meyer R. J., Jenkins J. K., Temple R., Krall R. L., Rosen C. J.
Extract | Full Text | PDF  
N Engl J Med 2007; published at www.nejm.org on Aug 29, 2007 (10.1056/NEJMc076347). Correspondence

This article has been cited by other articles:

• Gandhi, G. Y., Murad, M. H., Fujiyoshi, A., Mullan, R. J., Flynn, D. N., Elamin, M. B., Swiglo, B. A., Isley, W. L., Guyatt, G. H., Montori, V. M. (2008). Patient-Important Outcomes in Registered Diabetes Trials. JAMA 299: 2543-2549 [Abstract] [Full Text]  
• Dahabreh, I. J (2008). Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 5: 116-120 [Abstract]  
• Sanz, J., Moreno, P. R., Fuster, V. (2008). The year in atherothrombosis.. J Am Coll Cardiol 51: 944-955 [Full Text]  
• Shuster, J. J., Schatz, D. A. (2008). The Rosigliazone Meta-Analysis: Lessons for the future. Diabetes Care 31: e10-e10 [Full Text]  
• Barnett, A. H (2008). Thiazolidinediones and cardiovascular outcomes. British Journal of Diabetes & Vascular Disease 8: 45-49 [Abstract]  
• Hadler, N. M. (2008). Oral Hypoglycemics and Diabetic Nephropathy. CJASN 3: 159-162 [Full Text]  
• Hlatky, M. A, Bravata, D. M (2007). Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes. Evid. Based Med. 12: 169-170 [Full Text]  
• Joffe, H. V., Parks, M. H., Meyer, R. J., Jenkins, J. K., Temple, R., Krall, R. L., Rosen, C. J. (2007). Rosiglitazone and the FDA. NEJM 357: 1775-1777 [Full Text]  
• Mulrow, C. D., Cornell, J., Localio, A. R. (2007). Rosiglitazone: A Thunderstorm from Scarce and Fragile Data. ANN INTERN MED 147: 585-587 [Full Text]